MarkAngelAgiusMD

Neurology • Woodland, CA

Professor, Neurology, UC, Davis School of Medicine

Join to view full profile

Dr. Agius is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agius' full profile

Already have an account?

Office
515 Fairchild Ct
Woodland, CA 95695
Phone+1 530-668-2600

Fax+1 530-669-3661

Education & Training

Boston University Medical CenterResidency, Neurology, 1980 - 1983
University of Malta School of MedicineClass of 1977

Certifications & Licensure

CA State Medical License 1992 - 2026
AZ State Medical License 2015 - 2025
IL State Medical License 1983 - 1993
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Cannabis for Spasticity in Multiple Sclerosis Start of enrollment: 2003 Mar 01
Terminated
Phase 1, Phase 2
Cannabis for Spasticity in Multiple Sclerosis Start of enrollment: 2004 Apr 14
Terminated
Phase 1, Phase 2
Serum Auto-Antibodies in Neurological Diseases Start of enrollment: 2002 Jan 01
Enrolling by invitation
Lido Workset Study Start of enrollment: 2003 Apr 01
Completed
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis Start of enrollment: 2011 Mar 01
Completed
Phase 3
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2013 Nov 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

58 citations
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruce A.C. Cree, Gary Cutter, Jerry S. Wolinsky, M. S. Freedman, Giancarlo Comi
The Lancet. Neurology. 2020-12-01
37 citations
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo
Multiple Sclerosis. 2020-01-01
96 citations
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 ra...
Mark Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, Andrzej Potemkowski, Jing Li
Multiple Sclerosis. 2019-02-01

Grant Support

Immune Network In MyastheniaNational Institute Of Neurological Disorders And Stroke1991–1992
Immune Network In MyastheniaNational Institute Of Neurological Disorders And Stroke1990